Table 3.

Change from Baseline to 6 Months in Lipid Peroxides in Serum (μM), by Treatment Group and SOD2 Genotype

Basal Oxidative State
Month 6 - Baseline	Ala/Ala		Ala/Val		Val/Val
Treatment Group	N	Median (Range)	N	Median (Range)	N	Median (Range)
Control	3	3.7 (−14.9, 16)	8	4.7 (−2.1, 19)	3	7.6 (1.2, 39)
Treatment	19	−0.2 (−25.2, 22)	38	−1.6 (−20, 50.1)	12	−4.9 (−15.4, 49.9)

AAPH Oxidative State
Month 6 - Baseline	Ala/Ala		Ala/Val		Val/Val
Treatment Group	N	Median (Range)	N	Median (Range)	N	Median (Range)
Control	3	209.8 (−72.6, 217.6)	8	−5.3 (−12.6, 20.3)	3	−24.5 (−25.6, 160.6)
Treatment	19	11.3 (−266.2, 260.5)	38	−3.7 (−218.7, 273.3)	12	−16.8 (−223.7, 107.1)

Change in Lipid Peroxides in Serum (microM)
Measure/Dose Level	Ala/Ala		Ala/Val		Val/Val
	N	Change in LP	N	Change in LP	N	Change in LP
Basal Oxidative State		Median (Range)		Median (Range)		Median (Range)
Control	4	−2.4 (−14.9 – 16)	8	5.8 (−2.1 – 19)	3	15.9 (1.2 – 39)
Low-Dose	11	1 (−25.2 – 22)	19	0.7 (−20 – 50.1)	10	−0.1 (−15.4 – 39)
High-Dose	8	9.8 (−3.2 – 24.6)	19	0.4 (−12.5 – 14.8)	2	8 (3 – 13)
AAPH Oxidative State
Control	4	77.4 (−72.6 – 217.6)	8	−0.5 (−12.6 – 20.3)	3	36.8 (−25.6 – 160.6)
Low-Dose	11	18.4 (−202.8 – 241.3)	19	17.1 (−209.2 – 262.9)	10	7.8 (−26 – 160.6)
High-Dose	8	37.7 (−266.2 – 260.5)	19	4.1 (−218.7 – 273.3)	2	−159.7 (−223.7 – −95.7)

Treatment: combined high and low dose MPX, AAPH: 2,2-azobis(2-amidino-propane) dihydrochloride.